Latest Advances in PDX Modelling for Oncology Drug Discovery
News Sep 13, 2013
Preclinical Oncology Services Limited (PRECOS) has announced the availability of its co-presentation with Crown Bioscience delivered at the Tumor Models Boston 2013 meeting.
The presentation highlights the application of human surrogate trials to oncology drug discovery and how a comprehensive panel of PDX (Patient-Derived Xenograft) models of cancer can help better predict the effectiveness of drugs in clinical trials.
Historically the oncology drug development process is slow, expensive, inefficient and ultimately unsustainable. PRECOS and Crown Bioscience recognize the need to bring clinical decision-making earlier into the process.
Dr Aaron Cranston, Head of in vivo services, PRECOS Ltd comments, “Translating oncology drug discovery into improved patient outcome is the fundamental mission for both PRECOS and Crown Biosciences. By using human surrogate trials (HuTrials®) it is possible to identify biomarker signatures of patient responders and non-responders following treatment with targeted agents, reduce the attrition rate of new chemical entities (NCEs) in the clinic, accelerating drug development and improve chances of translational success.
By focusing on developing tumor models that are truly representative of patient outcomes, PRECOS and Crown Biosciences enable drug developers to overcome the challenges faced in preclinical oncology when testing new cancer drugs.
Problems in oncology drug development include a failure to consistently deliver highly effective drugs to patients, with many new drugs providing incremental benefit at non-incremental costs.
The ultimate goal in the oncology community is effective drug performance in the clinic and PDX models are superior in predicting efficacy and mimicking tumour activity in patients.
Also known as tumor graft models, PDXs are based on the transfer of primary tumors directly from the patient into an immunodeficient mouse.
PRECOS presented alongside its parent company Crown Bioscience on the latest developments in PDX modelling, highlighting the scale and skill of Crown Bioscience’s resources to maintain hundreds of in vivo PDX models in simultaneous passage ready for screening.
The presentation illustrates how PDX are being used today to discover biomarkers and run human surrogate trials using the world’s most comprehensive commercially available PDX collection.
Dr Cranston continues, “PRECOS is committed to developing improved preclinical models and providing researchers with the very best oncology tools for superior predictions, which will ultimately lead to enhanced patient response. Molecular profiling and characterization underpins the models and the innovative approaches developed by PRECOS enable scientists to fast-track new agents into the clinic.”
Tumor Models 2013 was hosted in Boston from 23rd - 25th July. The meeting was attended by international researchers interested in optimizing models, exploring alternatives and predicting efficacy for enhanced clinical performance.